During the last session, Kazia Therapeutics Limited ADR (NASDAQ:KZIA)’s traded shares were 98718.0, with the beta value of the company hitting 2.48. At the end of the trading day, the stock’s price was $8.91, reflecting an intraday loss of -4.50% or -$0.42. The 52-week high for the KZIA share is $79.00, that puts it down -786.64 from that peak though still a striking 67.9% gain since the share price plummeted to a 52-week low of $2.86. The company’s market capitalization is $8.64M, and the average intraday trading volume over the past 10 days was 5.17 million shares, and the average trade volume was 830.18K shares over the past three months.
Kazia Therapeutics Limited ADR (KZIA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. KZIA has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Kazia Therapeutics Limited ADR (NASDAQ:KZIA) trade information
Kazia Therapeutics Limited ADR (KZIA) registered a -4.50% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.50% in intraday trading to $8.91, hitting a weekly high. The stock’s 5-day price performance is -6.60%, and it has moved by 144.78% in 30 days. Based on these gigs, the overall price performance for the year is -22.54%. The short interest in Kazia Therapeutics Limited ADR (NASDAQ:KZIA) is 14394.0 shares and it means that shorts have 0.58 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 11.47%.
KZIA Dividends
Kazia Therapeutics Limited ADR is due to release its next quarterly earnings in July. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Kazia Therapeutics Limited ADR (NASDAQ:KZIA)’s Major holders
Kazia Therapeutics Limited ADR insiders own 10.09% of total outstanding shares while institutional holders control 8.22%, with the float percentage being 9.14%. BNP PARIBAS ARBITRAGE, SNC is the largest shareholder of the company, while 11.0 institutions own stock in it. As of 2024-06-30, the company held over 63568.0 shares (or 0.2651% of all shares), a total value of $14532.0 in shares.
The next largest institutional holding, with 41478.0 shares, is of SUSQUEHANNA INTERNATIONAL GROUP, LLP’s that is approximately 0.173% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $9457.0.
